Health Canada speeds up drug approvals: what it means for hormone-therapy access

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Health Canada announced on July 16, 2026 that it has issued a new order allowing the department to rely on drug-approval decisions and documents from certain trusted foreign regulatory authorities, cutting what it called "unnecessary duplication" while keeping Canadian standards for safety, efficacy, and quality intact. For Canadians on hormone therapy, or waiting to start it, the practical question is whether this change will finally close the gap between what is available in the United States or Europe and what sits on Canadian pharmacy shelves.

The announcement matters to hormone-care patients because that gap is real. The Canadian Organization for Rare Disorders has documented that only about 60 percent of treatments for rare disorders reach Canada, often arriving up to six years after US approval. Hormone therapies are not rare-disease drugs, but the same slow review machinery has historically delayed Canadian access to newer formulations of estradiol (sold in Canada as Estrace in oral form and Estradot as a patch), progesterone (Prometrium), and testosterone products used in gender-affirming care. A faster pathway could mean shorter waits for patients whose clinicians are already prescribing off-label or compounded alternatives because the approved Canadian option does not exist yet.

What this means in Canada

Health Canada has not published a specific list of hormone drugs that will move through the new expedited stream. The department said it will begin applying the approach to pediatric drugs and veterinary drugs first, with broader rollout to follow. It is also consulting on a parallel proposal to prioritize reviews involving Canadian manufacturing, which could affect generic hormone products made domestically.

On the generic front, Health Canada separately noted it is the first G7 country to approve three generic versions of semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for weight management). That approval is unrelated to hormone therapy but signals the department is willing to move quickly when it chooses to.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement on the new expedited-approval order as of publication. Provincial pharmacare programs, including Ontario's OHIP-linked drug benefit (ODB), Quebec's RAMQ, British Columbia's PharmaCare, and Alberta's AHCIP, cover hormone therapies selectively. Coverage decisions follow Health Canada approval, so a faster federal green light is a prerequisite for any provincial formulary listing, but it does not guarantee one.

Canadian telehealth platforms that prescribe hormone therapy, including Cleo (a Canadian women's-health platform), Felix (a Canadian online pharmacy and prescribing service), and Science & Humans (scienceandhumans.com), are bound by the same Health Canada-approved drug list as any brick-and-mortar clinic. A broader approved formulary would expand what these platforms can prescribe without compounding.

What changed

Before this order, Health Canada conducted largely independent reviews of every drug submission, even when the US Food and Drug Administration (FDA), the European Medicines Agency, or another peer regulator had already completed a rigorous assessment. The new approach lets Health Canada accept or rely on those foreign reviews as part of its own process, rather than starting from scratch.

York University professor emeritus Joel Lexchin, writing for the Canadian Centre for Policy Alternatives in March 2026, argued that critics of the old system were "overblowing" the problem, pointing out that Health Canada has historically approved at least 70 percent of drugs approved by the FDA, with an even higher rate for cancer drugs. His argument is that the approval rate was never the core issue; the delay was. The new order addresses delay directly by removing duplicative review steps.

Health Canada also reported that over the three months before the announcement, it approved 537 new drugs and medical devices, suggesting the department has been accelerating reviews ahead of formalizing the new framework.

What Canadian patients should know

If you are currently on a Health Canada-approved hormone therapy, nothing changes for you immediately. Your prescription, your pharmacy, and your provincial drug coverage are unaffected by this announcement.

If you have been told by a clinician that a specific formulation you need is not yet approved in Canada, it is worth asking your doctor or pharmacist to check Health Canada's drug product database in the coming months. The expedited pathway is new, and the department has not published a timeline for which drug categories come after pediatric and veterinary products.

Patients in Ontario can check the ODB formulary through the Ontario Drug Benefit program. Quebec patients can check the RAMQ list of covered medications. BC residents can consult the BC PharmaCare drug coverage search. These provincial lists update independently of Health Canada approvals, so a newly approved drug may take additional months to appear on a provincial formulary.

For gender-affirming hormone care specifically, access varies sharply by province. BC and Ontario have the most established publicly funded pathways. Patients in provinces with fewer specialist resources sometimes use platforms like Cleo or Felix for initial prescribing, but those platforms can only prescribe what Health Canada has approved.

US-based hormone-care telehealth platforms such as Midi Health, Hone Health, and Winona are not licensed to serve Canadian patients and cannot prescribe to Canadian addresses.

Limitations and open questions

Health Canada has not named the foreign regulators whose decisions it will rely on. The FDA is the most obvious candidate, but the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency are also possibilities. The choice matters: the FDA and EMA sometimes reach different conclusions on the same drug.

The order also does not specify what "rely on" means in practice. Full reliance (accepting a foreign approval as sufficient) is different from partial reliance (using foreign data to shorten but not replace a Canadian review). Health Canada's consultation on Canadian-manufacturing prioritization is still open, meaning that aspect of the policy is not yet finalized.

The SOGC has not weighed in on whether the new pathway is likely to benefit hormone-therapy patients specifically. The Canadian Institutes of Health Research (CIHR) has not announced any linked research funding to study outcomes under the new approval model.

Finally, faster approval does not mean faster coverage. Provincial pharmacare programs run their own health technology assessments, often through the Canadian Drug Agency (formerly CADTH). A drug can be Health Canada-approved for months or years before it appears on a provincial formulary. That second gate remains unchanged by this order.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.